Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEISMiC-C trial of istaroxime in SCAI stage C cardiogenic shock
MOH_2023-11-07_012930Phase 2Completed
- Sponsor
- Windtree Therapeutics, Inc.
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in cardiogenic shock and heart failure (HF) comparing Istaroxime with Placebo (2 arms). Primary endpoint: Change in systolic blood pressure. Started Oct 2023; status: completed.
02
Drugs
istaroxime
03
Conditions
cardiogenic shockheart failure (HF)
Beyond the preview
Go deeper on MOH_2023-11-07_012930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-11-07_012930.